This is a preview of subscription content, log in via an institution to check access.
Notes
2017 US dollars
Reference
Sussman M, et al. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. Cephalalgia : 24 Aug 2018. Available from: URL: http://doi.org/10.1177/0333102418796842
Rights and permissions
About this article
Cite this article
Erenumab cost effective for chronic but not episodic migraine. PharmacoEcon Outcomes News 811, 11 (2018). https://doi.org/10.1007/s40274-018-5240-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5240-4